Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TERCONAZOLE

1 general benefit · 1 not a benefit

Other products in the same Health Canada class (G01A) — coverage varies; not interchangeable

  • Clotrimazole (Clotrimaderm): general benefit, Not a benefit
  • Nystatin (Mycostatin): general benefit, Not a benefit

Taro-Terconazole · DIN 02247651 · 0.4% · Vag Cr

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Terconazole · DIN 02247651 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2005-06-13 Health Canada: Marketed since 2004-09-21 · brand TARO-TERCONAZOLE · ATC G01AG02 TERCONAZOLE · form Cream · route Vaginal · ingredients TERCONAZOLE 0.4 % · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Terconazole: Formulary list price $0.6354/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6354 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71914 · Verify on the e-Formulary ↗ (DIN 02247651)

Source record
DIN 02247651: Taro-Terconazole Raw flags: sec3=Y Item: 840408042; group id 825; item number 2010; lccId None; manufacturer id TAR Source form: Vag Cr; strength: 0.4% Recorded listing: General benefit Source prices (unrounded): $0.6354; ministry $0.6354 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247651 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71914
Interchangeable products
Terazol 7 · DIN 00894729 · not recorded
Shortage status: resolved shortage (ended 2020-03-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247651
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Terazol 7 · DIN 00894729 · 0.4% · Vag Cr

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-11-30 — choose a marketed DIN from the same-category list.Discontinued 2016-11-30 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-11-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2016-11-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Terazol 7 · DIN 00894729 Manufacturer: Janssen Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2016-11-30 · brand TERAZOL 7 VAGINAL CREAM 0.4% · ATC G01AG02 TERCONAZOLE · form Cream · route Vaginal · ingredients TERCONAZOLE 4 MG/G · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Terazol 7: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11460 · Verify on the e-Formulary ↗ (DIN 00894729)

Source record
DIN 00894729: Terazol 7 Raw flags: notABenefit=Y, sec3=Y Item: 840408042; group id 825; item number 2010; lccId None; manufacturer id JAN Source form: Vag Cr; strength: 0.4% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00894729 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11460
Interchangeable products
Taro-Terconazole · DIN 02247651 · $0.6354
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00894729
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2016-11-30 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): CLOTRIMAZOLE, KETOCONAZOLE, NYSTATIN 84:04:08 Fungicides

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

KETOCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Cr

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

FLUCONAZOLE

· 8 products · Limited Use, codes 235 · strengths: 150mg · Cap

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% w/w & 0.05% w/w · Top Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TARO-TERCONAZOLE (terconazole) Vaginal Cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). The diagnosis of monilial infection should be confirmed by TARO-TERCONAZOLE Vaginal Cream 0.4% Product Monograph Page 2 of 21 microscopic examination of a KOH smear and/or by culture. TARO-TERCONAZOLE vaginal cream may be used in pregnant patients during the second and third trimester if the physician considers it essential to the welfare of the patient (see PRECAUTIONS, Use During Pregnancy). The therapeutic effect of TARO-TERCONAZOLE vaginal cream is not affected by oral contraceptive usage, menstruation or previous monilial infection. https://pdf.hres.ca/dpd_pm/00064148.PDF PM date: December 23, 2021 Source product: TARO-TERCONAZOLE; DIN 02247651; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Terazol 7: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026